{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:51:46Z","timestamp":1781596306587,"version":"3.54.5"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hainan Province Clinical Medical Center","award":["Grant No. QWYH202175"],"award-info":[{"award-number":["Grant No. QWYH202175"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10067-025-07825-x","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T02:56:11Z","timestamp":1764039371000},"page":"831-844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A bibliometric analysis on immunotherapy treatments for systemic lupus erythematosus: analysis of published evidence from 2014 to 2024"],"prefix":"10.1007","volume":"45","author":[{"given":"Datian","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingdong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9457-5339","authenticated-orcid":false,"given":"Haimei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"6","key":"7825_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.41632","volume":"73","author":"PM Izmirly","year":"2021","unstructured":"Izmirly PM, Parton H, Wang L et al (2021) Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the centers for disease control and prevention national lupus registries. Arthritis Rheumatol 73(6):991\u2013996. https:\/\/doi.org\/10.1002\/art.41632","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"7825_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.semarthrit.2008.10.007","volume":"39","author":"GJ Pons-estel","year":"2010","unstructured":"Pons-estel GJ, Alarc\u00f3n GS, Scofield L et al (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39(4):257\u2013268. https:\/\/doi.org\/10.1016\/j.semarthrit.2008.10.007","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"7825_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","volume":"56","author":"F Rees","year":"2017","unstructured":"Rees F, Doherty M, Grainge MJ et al (2017) The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology 56(11):1945\u20131961. https:\/\/doi.org\/10.1093\/rheumatology\/kex260","journal-title":"Rheumatology"},{"issue":"5","key":"7825_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1191\/0961203306lu2305xx","volume":"15","author":"N Danchenko","year":"2006","unstructured":"Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15(5):308\u2013318. https:\/\/doi.org\/10.1191\/0961203306lu2305xx","journal-title":"Lupus"},{"issue":"12","key":"7825_CR5","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00296-022-05183-4","volume":"42","author":"F Fatoye","year":"2022","unstructured":"Fatoye F, Gebrye T, Mbada C (2022) Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis. Rheumatol Int 42(12):2097\u20132107. https:\/\/doi.org\/10.1007\/s00296-022-05183-4","journal-title":"Rheumatol Int"},{"issue":"12","key":"7825_CR6","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1136\/annrheumdis-2017-211663","volume":"76","author":"MG Tektonidou","year":"2017","unstructured":"Tektonidou MG, Lewandowski LB, Hu J et al (2017) Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 76(12):2009\u20132016. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211663","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"7825_CR7","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","volume":"74","author":"IN Bruce","year":"2015","unstructured":"Bruce IN, O\u2019keeffe AG, Farewell V et al (2015) Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis 74(9):1706\u20131713. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205171","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7825_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","volume":"80","author":"A Fanouriakis","year":"2021","unstructured":"Fanouriakis A, Tziolos N, Bertsias G et al (2021) Update \u03bfn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 80(1):14\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218272","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7825_CR9","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.2174\/0929867327666200625150408","volume":"28","author":"X Zhao","year":"2021","unstructured":"Zhao X, Zhang J, Liang Y et al (2021) Advances in drug therapy for systemic lupus erythematosus. Curr Med Chem 28(6):1251\u20131268. https:\/\/doi.org\/10.2174\/0929867327666200625150408","journal-title":"Curr Med Chem"},{"issue":"6","key":"7825_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736\u2013745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"key":"7825_CR11","doi-asserted-by":"publisher","unstructured":"Lo MS, Tsokos GC (2012) Treatment of systemic lupus erythematosus: new advances in targeted therapy [M]\/\/Rose N R. Year in Immunology 138\u2013152. https:\/\/doi.org\/10.1111\/j.1749-6632.2011.06263.x","DOI":"10.1111\/j.1749-6632.2011.06263.x"},{"key":"7825_CR12","doi-asserted-by":"publisher","unstructured":"Tan SZ, Li DP, Zhu X (2020) Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacother 124.  https:\/\/doi.org\/10.1016\/j.biopha.2020.109821","DOI":"10.1016\/j.biopha.2020.109821"},{"issue":"1","key":"7825_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders H J, Saxena R, Zhao M H, et al. Lupus nephritis [J]. NAture reviews disease primers, 2020, 6(1). https:\/\/doi.org\/10.1038\/s41572-019-0141-9","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"7825_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1124\/jpet.123.001744","volume":"388","author":"A Deshmukh","year":"2024","unstructured":"Deshmukh A, Pereira A, Geraci N et al (2024) Preclinical evidence for the glucocorticoid-sparing potential of a dual toll-like receptor 7\/8 inhibitor in autoimmune diseases. J Pharmacol Exp Ther 388(3):751\u2013764. https:\/\/doi.org\/10.1124\/jpet.123.001744","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"7825_CR15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/1756-185X.12500","volume":"17","author":"T Konstantinos","year":"2014","unstructured":"Konstantinos T, Alexandros S, Ioannis G et al (2014) Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus. Int J Rheum Dis 17(7):788\u2013793. https:\/\/doi.org\/10.1111\/1756-185X.12500","journal-title":"Int J Rheum Dis"},{"issue":"17","key":"7825_CR16","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel CH, Sammaritano LR (2024) Systemic lupus erythematosus. JAMA 331(17):1480\u20131491. https:\/\/doi.org\/10.1001\/jama.2024.2315","journal-title":"JAMA"},{"issue":"2","key":"7825_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","volume":"101","author":"BH Rovin","year":"2022","unstructured":"Rovin BH, Furie R, Teng YKO et al (2022) A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101(2):403\u2013413. https:\/\/doi.org\/10.1016\/j.kint.2021.08.027","journal-title":"Kidney Int"},{"issue":"7","key":"7825_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1177\/0961203320913944","volume":"29","author":"G Elolemy","year":"2020","unstructured":"Elolemy G, Al Rashidi A, Dehrab A et al (2020) Successful treatment of refractory lupus erythematosus profundus with the interleukin-6 antagonist tocilizumab: a case report. Lupus 29(7):791\u2013794. https:\/\/doi.org\/10.1177\/0961203320913944","journal-title":"Lupus"},{"issue":"20","key":"7825_CR19","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.2169\/internalmedicine.5362-25","volume":"64","author":"T Matsubara","year":"2025","unstructured":"Matsubara T, Takita M, Sekai I et al (2025) Development of diffuse large B cell lymphoma in a patient with systemic lupus erythematosus within two years after the initiation of anifrolumab and mycophenolate mofetil treatment. Internal Medicine 64(20):3044\u20133050. https:\/\/doi.org\/10.2169\/internalmedicine.5362-25","journal-title":"Internal Medicine"},{"issue":"15","key":"7825_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158411","volume":"23","author":"J Guiteras","year":"2022","unstructured":"Guiteras J, Crespo E, Fontova P et al (2022) Dual costimulatory and coinhibitory targeting with a hybrid fusion protein as an immunomodulatory therapy in lupus nephritis mice models. International Journal of Molecular Sciences 23(15):8411. https:\/\/doi.org\/10.3390\/ijms23158411","journal-title":"International Journal of Molecular Sciences"},{"key":"7825_CR21","doi-asserted-by":"publisher","unstructured":"Huang FG, Sun K, Zhou JW et al (2025) Decoding tryptophan: pioneering new frontiers in systemic lupus erythematosus. Autoimmun Rev  24(6).  https:\/\/doi.org\/10.1016\/j.autrev.2025.103809","DOI":"10.1016\/j.autrev.2025.103809"},{"issue":"3","key":"7825_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/08923973.2019.1616754","volume":"41","author":"CC Qiu","year":"2019","unstructured":"Qiu CC, Atencio AE, Gallucci S (2019) Inhibition of fatty acid metabolism by etomoxir or TOFA suppresses murine dendritic cell activation without affecting viability. Immunopharmacol Immunotoxicol 41(3):361\u2013369. https:\/\/doi.org\/10.1080\/08923973.2019.1616754","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"19","key":"7825_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910511","volume":"25","author":"HM Abdalhadi","year":"2024","unstructured":"Abdalhadi HM, Chatham WW, Alduraibi FK (2024) CAR-T-cell therapy for systemic lupus erythematosus: a comprehensive overview. International Journal OF Molecular Sciences 25(19):10511. https:\/\/doi.org\/10.3390\/ijms251910511","journal-title":"International Journal OF Molecular Sciences"},{"key":"7825_CR24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jconrel.2025.02.049","volume":"380","author":"X Qin","year":"2025","unstructured":"Qin X, Zhang M, Liang JL et al (2025) Nanoparticles encapsulating antigenic peptides induce tolerogenic dendritic cells in situ for treating systemic lupus erythematosus. J Control Release 380:943\u2013956. https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.049","journal-title":"J Control Release"},{"key":"7825_CR25","doi-asserted-by":"publisher","unstructured":"Han M, Niu H, Duan F et al (2024) Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis. Front Oncol 14. https:\/\/doi.org\/10.3389\/fonc.2024.1383805.","DOI":"10.3389\/fonc.2024.1383805"},{"key":"7825_CR26","doi-asserted-by":"publisher","unstructured":"Li R, Zhang R, Jia Y et al (2024) A bibliometric analysis from 2004 to 2024 reveals research hotspots and trends in the immunotherapy for vasculitis. Hum Vaccines Immunother 20(1).  https:\/\/doi.org\/10.1080\/21645515.2024.2420446","DOI":"10.1080\/21645515.2024.2420446"},{"key":"7825_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2420446","author":"R Zhang","year":"2024","unstructured":"Zhang R, Li Y, Nie Z (2024) A bibliometric analysis from 2014 to 2024 reveals research hotspots and trends in the immunotherapy for glomerulonephritis. Hum Vaccin Immunother. https:\/\/doi.org\/10.1080\/21645515.2024.2420446","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"7825_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.heliyon.2024.e33350","volume":"10","author":"Z Yuan","year":"2024","unstructured":"Yuan Z, Zhang W, Jin Z et al (2024) Global research trends in precision-targeted therapies for systemic lupus erythematosus (2003\u20132023): a bibliographic study. Heliyon 10(13):1\u201317. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33350","journal-title":"Heliyon"},{"issue":"5","key":"7825_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M et al (2017) Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69(5):1016\u20131027. https:\/\/doi.org\/10.1002\/art.40049","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"7825_CR30","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","volume":"74","author":"RA Furie","year":"2015","unstructured":"Furie RA, Leon G, Thomas M et al (2015) A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis 74(9):1667\u20131675. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205144","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7825_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40272-021-00457-z","volume":"23","author":"VC Trindade","year":"2021","unstructured":"Trindade VC, Carneiro-Sampaio M, Bonfa E et al (2021) An update on the management of childhood-onset systemic lupus erythematosus. Pediatr Drugs 23(4):331\u2013347. https:\/\/doi.org\/10.1007\/s40272-021-00457-z","journal-title":"Pediatr Drugs"},{"key":"7825_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031263","author":"C Rafael-Vidal","year":"2021","unstructured":"Rafael-Vidal C, ALTAB\u00e1S I, P\u00e9REZ N et al (2021) Calcineurin and systemic lupus erythematosus: the rationale for using calcineurin inhibitors in the treatment of lupus nephritis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22031263","journal-title":"Int J Mol Sci"},{"key":"7825_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-025-05879-3","author":"C Staveri","year":"2025","unstructured":"Staveri C, Lykoura C, Melissaropoulos K et al (2025) Favorable outcomes for patients with refractory systemic lupus erythematosus treated with rituximab as evidenced with a follow-up of \u2265 10 years: a real-world evidence study. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-025-05879-3","journal-title":"Rheumatol Int"},{"issue":"3","key":"7825_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/1744666X.2023.2172404","volume":"19","author":"L Laigle","year":"2023","unstructured":"Laigle L, Chadli L, Moingeon P (2023) Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises. Expert Rev Clin Immunol 19(3):305\u2013314. https:\/\/doi.org\/10.1080\/1744666X.2023.2172404","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"7825_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/rheumatology\/kead629","volume":"64","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Qi FM, Bai JY et al (2023) Real-world efficacy of belimumab in systemic lupus erythematosus: a prospective cohort from a single centre in China. Rheumatology 64(1):108\u2013116. https:\/\/doi.org\/10.1093\/rheumatology\/kead629","journal-title":"Rheumatology"},{"issue":"3","key":"7825_CR36","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10067-021-05931-0","volume":"41","author":"JC JAIME-P\u00e9REZ","year":"2022","unstructured":"JAIME-P\u00e9REZ JC, GONZ\u00e1LEZ-TREVI\u00f1O M, MEL\u00e9NDEZ-FLORES JD et al (2022) Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort. Clin Rheumatol 41(3):869\u2013876. https:\/\/doi.org\/10.1007\/s10067-021-05931-0","journal-title":"Clin Rheumatol"},{"key":"7825_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210161","author":"BW Lee","year":"2023","unstructured":"Lee BW, Kwok SK (2023) Mesenchymal stem\/stromal cell-based therapies in systemic rheumatic disease: from challenges to new approaches for overcoming restrictions. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241210161","journal-title":"Int J Mol Sci"},{"key":"7825_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16091176","author":"NR Kundnani","year":"2024","unstructured":"Kundnani NR, Levai MC, Popa MD et al (2024) Biologics in systemic lupus erythematosus: recent evolutions and benefits. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics16091176","journal-title":"Pharmaceutics"},{"issue":"5","key":"7825_CR39","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1177\/0961203321990107","volume":"30","author":"V Shobha","year":"2021","unstructured":"Shobha V, Mohan A, Malini A et al (2021) Identification and stratification of systemic lupus erythematosus patients into two transcriptionally distinct clusters based on IFN-I signature. Lupus 30(5):762\u2013774. https:\/\/doi.org\/10.1177\/0961203321990107","journal-title":"Lupus"},{"key":"7825_CR40","doi-asserted-by":"publisher","unstructured":"Xiang MM, Wang YL, Gao ZY et al (2023) Exploring causal correlations between inflammatory cytokines and systemic lupus erythematosus: a Mendelian randomization. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.985729","DOI":"10.3389\/fimmu.2022.985729"},{"issue":"03","key":"7825_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.16150\/j.1671-2870.2024.03.002","volume":"23","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhao S, Xuebing F (2024) Current status and challenges in diagnosis and treatment of systemic lupus erythematosus in China. Journal of Diagnostics Concepts & Practice 23(03):257\u2013262. https:\/\/doi.org\/10.16150\/j.1671-2870.2024.03.002","journal-title":"Journal of Diagnostics Concepts & Practice"},{"issue":"10","key":"7825_CR42","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcLLER F, Mougiakakos D et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132. https:\/\/doi.org\/10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"issue":"6","key":"7825_CR43","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, KR\u00f6NKE G, V\u00f6LKL S et al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385(6):567\u2013569. https:\/\/doi.org\/10.1056\/NEJMc2107725","journal-title":"N Engl J Med"},{"issue":"12","key":"7825_CR44","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jama.2018.22123","volume":"321","author":"DB Johnson","year":"2019","unstructured":"Johnson DB, Chandra S, Sosman JA (2019) Adverse events associated with immune checkpoint inhibitors reply. JAMA 321(12):1219\u20131220. https:\/\/doi.org\/10.1001\/jama.2018.22123","journal-title":"JAMA"},{"issue":"1","key":"7825_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He J, Zhang RJ, Shao M et al (2020) Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 79(1):141\u2013149. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215396","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7825_CR46","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/0961203317749047","volume":"27","author":"S Iwata","year":"2018","unstructured":"Iwata S, Saito K, Hirata S et al (2018) Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus 27(5):802\u2013811. https:\/\/doi.org\/10.1177\/0961203317749047","journal-title":"Lupus"},{"issue":"3","key":"7825_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14712598.2023.2178297","volume":"23","author":"W Stohl","year":"2023","unstructured":"Stohl W, Kwok A (2023) Belimumab for the treatment of pediatric patients with lupus nephritis. Expert Opin Biol Ther 23(3):243\u2013251. https:\/\/doi.org\/10.1080\/14712598.2023.2178297","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"7825_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","volume":"77","author":"FC Zhang","year":"2018","unstructured":"Zhang FC, Bae SC, Bass D et al (2018) A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 77(3):355\u2013363. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211631","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"7825_CR49","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s40265-021-01604-z","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED (2021) Anifrolumab: first approval. Drugs 81(15):1795\u20131802. https:\/\/doi.org\/10.1007\/s40265-021-01604-z","journal-title":"Drugs"},{"issue":"7","key":"7825_CR50","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/annrheumdis-2021-221425","volume":"81","author":"EM Vital","year":"2022","unstructured":"Vital EM, Merrill JT, Morand EF et al (2022) Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis 81(7):951\u2013961. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221425","journal-title":"Ann Rheum Dis"},{"key":"7825_CR51","doi-asserted-by":"publisher","unstructured":"Zhou JC, Lei BX, Shi FF et al (2024) CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Front Immunol 1476859. https:\/\/doi.org\/10.3389\/fimmu.2024.1476859","DOI":"10.3389\/fimmu.2024.1476859"},{"issue":"4","key":"7825_CR52","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/art.42784","volume":"76","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, M\u00fcLLER F, Mutlu MY et al (2024) CD19 chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus. Arthritis Rheumatol 76(4):497\u2013504. https:\/\/doi.org\/10.1002\/art.42784","journal-title":"Arthritis Rheumatol"},{"issue":"10275","key":"7825_CR53","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, ENERB\u00e4CK C et al (2021) Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397(10275):754\u2013766. https:\/\/doi.org\/10.1016\/S0140-6736(21)00184-7","journal-title":"Lancet"},{"key":"7825_CR54","doi-asserted-by":"publisher","unstructured":"Wang Y, Chen SJ, Du KZ et al (2021) Traditional herbal medicine: therapeutic potential in rheumatoid arthritis. J Ethnopharmacol 279. https:\/\/doi.org\/10.1016\/j.jep.2021.114368","DOI":"10.1016\/j.jep.2021.114368"},{"issue":"18","key":"7825_CR55","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"XB Wang","year":"2024","unstructured":"Wang XB, Wu X, Tan BH et al (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187(18):4890\u20134904. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027","journal-title":"Cell"},{"issue":"2","key":"7825_CR56","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/bjh.18032","volume":"197","author":"SM Sengsayadeth","year":"2022","unstructured":"Sengsayadeth SM, Savani BN (2022) Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases. Br J Haematol 197(2):236\u2013236. https:\/\/doi.org\/10.1111\/bjh.18032","journal-title":"Br J Haematol"},{"issue":"6","key":"7825_CR57","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar BR, Murphy WJ, Abedi M (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12(6):443\u2013458. https:\/\/doi.org\/10.1038\/nri3212","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"7825_CR58","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.3260","volume":"19","author":"G Schett","year":"2013","unstructured":"Schett G, Elewaut D, McInnes IB et al (2013) How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 19(7):822\u2013824. https:\/\/doi.org\/10.1038\/nm.3260","journal-title":"Nat Med"},{"issue":"12","key":"7825_CR59","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","volume":"192","author":"MK Crow","year":"2014","unstructured":"Crow MK (2014) Type I interferon in the pathogenesis of lupus. J Immunol 192(12):5459\u20135468. https:\/\/doi.org\/10.4049\/jimmunol.1002795","journal-title":"J Immunol"},{"issue":"7","key":"7825_CR60","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","volume":"75","author":"C Von Spee-Mayer","year":"2016","unstructured":"Von Spee-Mayer C, Siegert E, Abdirama D et al (2016) Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis 75(7):1407\u20131415. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207776","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7825_CR61","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s10753-016-0470-8","volume":"40","author":"JH Tao","year":"2017","unstructured":"Tao JH, Cheng M, Tang JP et al (2017) Foxp3, regulatory T cell, and autoimmune diseases. Inflammation 40(1):328\u2013339. https:\/\/doi.org\/10.1007\/s10753-016-0470-8","journal-title":"Inflammation"},{"issue":"6","key":"7825_CR62","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","volume":"30","author":"M Miyara","year":"2009","unstructured":"Miyara M, Yoshioka Y, Kitoh A et al (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30(6):899\u2013911. https:\/\/doi.org\/10.1016\/j.immuni.2009.03.019","journal-title":"Immunity"},{"key":"7825_CR63","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2147\/JIR.S397639","volume":"16","author":"RX Huo","year":"2023","unstructured":"Huo RX, Huang XX, Yang Y et al (2023) Potential use of Janus kinase inhibitors in the treatment of systemic lupus erythematosus. J Inflamm Res 16:1471\u20131478. https:\/\/doi.org\/10.2147\/JIR.S397639","journal-title":"J Inflamm Res"},{"issue":"2","key":"7825_CR64","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.intimp.2014.10.003","volume":"23","author":"Y Jin","year":"2014","unstructured":"Jin Y, Wang LY, Liu DX et al (2014) Tamibarotene modulates the local immune response in experimental periodontitis. Int Immunopharmacol 23(2):537\u2013545. https:\/\/doi.org\/10.1016\/j.intimp.2014.10.003","journal-title":"Int Immunopharmacol"},{"key":"7825_CR65","doi-asserted-by":"publisher","unstructured":"Yu J, Mei J, Zuo DC et al (2024) Inflammatory factor-mediated miR-155\/SOCS1 signaling axis leads to Treg impairment in systemic lupus erythematosus. Int Immunopharmacol 141. https:\/\/doi.org\/10.1016\/j.intimp.2024.113013","DOI":"10.1016\/j.intimp.2024.113013"},{"key":"7825_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093389","author":"K Melissaropoulos","year":"2020","unstructured":"Melissaropoulos K, Klavdianou K, Filippopoulou A et al (2020) Rheumatic manifestations in patients treated with immune checkpoint inhibitors. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21093389","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7825_CR67","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","volume":"290","author":"SY Dai","year":"2014","unstructured":"Dai SY, Jia R, Zhang X et al (2014) The PD-1\/PD-Ls pathway and autoimmune diseases. Cell Immunol 290(1):72\u201379. https:\/\/doi.org\/10.1016\/j.cellimm.2014.05.006","journal-title":"Cell Immunol"},{"issue":"2","key":"7825_CR68","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/art.38260","volume":"66","author":"R Furie","year":"2014","unstructured":"Furie R, Nicholls K, Cheng TT et al (2014) Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 66(2):379\u2013389. https:\/\/doi.org\/10.1002\/art.38260","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07825-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07825-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07825-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:01:52Z","timestamp":1769763712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07825-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7825"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07825-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not necessary in this study, because we do not use human or animal data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"We are hereby granting irrevocable consent for the publication, reproduction, dissemination, and perpetual archival of all data, materials, and results generated through our participation in this research study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}